Document is current
Any future updates will be listed below
-
Authors
Bae, Cheong A.
Ham, In-Hye
Oh, Hye Jeong
Lee, Dagyeong
Woo, Jongsu
Son, Sang-Yong
Yoon, Jung Hwan
Lorens, James B.
Brekken, Rolf A.
Kim, Tae-Min
Han, Sang-Uk
Park, Won Sang
Hur, Hoon
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2019R1F1A1058915)
National Research Foundation of Korea (2019K1A3A1A20083809)
- License Information
-
More Information
Article History
Received: 20 September 2019
Accepted: 22 March 2020
First Online: 2 April 2020
Compliance with ethical standard
:
: R.A. Brekken has an ownership interest (including stock, patents, etc.) in and is a consultant/advisory board member for Tuevol Therapeutics. J.B. Lorens is a co-founder and shareholder of BerGenBio ASA. Other authors declare that they have no competing interests.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.
: Informed consent or an appropriate substitute for it was obtained from all patients included in the study.
Free to read: This content has been made available to all.
